December 17, 2020

Inside Address

RE: Inhaled Corticosteroid/Formoterol Combination Inhalers

Established in 1943, the American Academy of Allergy, Asthma & Immunology (Academy) is a professional association with nearly 7,000 members in the United States, Canada and 72 other countries. This membership includes allergist/immunologists (A/I), other medical specialists, allied health and related healthcare professionals—all with a special interest in the research and treatment of patients with allergic and immunologic diseases. On behalf of this membership, Academy leadership would like to draw your attention to the recent inclusion of inhaled corticosteroid/formoterol combination inhalers in the 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Expert Panel Working Group.

These recommendations, based on systematic reviews conducted by the Agency for Healthcare Research and Quality and input from National Asthma Education Prevention Program (NAEPP) participant organizations, medical experts, and the public, set forth 19 recommendations in six key areas of asthma diagnosis, management and treatment. Published in the *Journal of Allergy and Clinical Immunology*, the new guidance focuses on tailored treatment interventions for specific age groups, based on disease severity, using inhaled corticosteroid/formoterol combination inhalers, long-acting antimuscarinic antagonists, immunotherapy, indoor allergen mitigation, fractional exhaled nitric oxide testing, and bronchial thermoplasty.

Specifically, these guidelines recommend the use of an inhaled corticosteroid/formoterol combination inhaler for moderate and severe persistent asthma¹. To provide optimal patient care

¹ [https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates/faqs#topic1](https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates/faqs#topic1)
and reflect this standard of practice, the Academy respectfully requests that your prescription drug formulary classify inhaled corticosteroid/formoterol combination inhalers as preferred.

To discuss this comment further, please contact Renee Vandlik at RVandlik@aaaai.org or 414-272-6071. She will facilitate further communication with AAAAI leadership.

Sincerely,

Mary Beth Fasano, MD, MSPH, FAAAAI
President, American Academy of Allergy, Asthma & Immunology